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Abstract
Purpose: Marijuana is the most widely used illicit drug in the United States. However,
marijuana and cannabinoid derivatives have potential therapeutic uses. Studies in
cannabis users have yielded contradictory results with regard to long-term effects on
cognitive functions. There is no prospective study assessing this issue, and such studies
may raise ethical issues in humans, whereas mice have been shown to exhibit similar
cannabinoid-mediated behaviors as humans. The purpose of this study was to assess the
consequences of chronic administration of ∆9-THC, the major psychoactive component
of marijuana, in a mouse memory model.
Methods: In Experiment 1, the dose-response relationship of ∆9-THC was assessed in the
object recognition task, a well-documented rodent memory model. In Experiment 2, mice
were treated repeatedly with either escalating doses of ∆9-THC or vehicle for one week,
and then challenged with the drug to assess whether tolerance had developed.
Results: Acute ∆9-THC dose-dependently interfered with memory as assessed in the
object recognition task (ED50 95% C.I. = 0.5 (0.1 to1.7) mg/kg). No tolerance to the
memory disruptive effects of 1 mg/kg ∆9-THC was evident after chronic treatment.
Conclusions: Considerably low doses of ∆9-THC impaired memory. The failure of
chronic ∆9-THC to produce tolerance in this model was surprising considering that a
similar dosing regimen has been reported to produce tolerance in non-mnemonic
behaviors. The results suggest that memory is particularly sensitive to the disruptive
effects of ∆9-THC and chronic cannabis use is likely to elicit persistent impairment of
cognitive function. Caution should be applied in advocating chronic use of medicinal
cannabinoids. Potential solutions lie in reinforcing education on the harm caused by
cannabis use and availability of alternative solution to cannabis users, especially among
youth that have shown to be more vulnerable to this drug.
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Introduction

Marijuana, also known as Cannabis sativa, is the most widely abused illicit drug
in the United States (US). The 2002 National Survey on Drug Use and Health (NSDUH)
reported that 14.6 million people have used marijuana in the month preceding the survey
(1). The same survey reported an estimated 2.6 million new marijuana users for that year.
A contributing factor to its widespread use is that marijuana is generally perceived as less
harmful than other drugs and is fairly easy to obtain. This same belief prevails among US
youth. In the National Vital Statistics report for 2001, 22.4% of high school seniors in the
US reported to have smoked marijuana in the month preceding the survey (2). According
to the NSDUH, 20.6 percent of youths aged 12 to 17 and 53.8 percent of young adults
aged 18 to 25 had used marijuana at least once, with 55.0 percent of youths reporting that
it was fairly or very easy to obtain marijuana (1). In 2003, 17.5, 36.4 and 46.1 percent of
respective 8th, 10th and 12th graders in the US reported to have used marijuana at least
once, and 44.8%, 73.9% and 87% of respective 8th, 10th and 12th graders reported this
drug as being accessible (3).
Despite the high rate of youth abusing marijuana, it is now established that acute
intoxication with marijuana disrupts short-term memory and problem solving, distorts
perception, and impairs coordination in humans as well in laboratory animals (4). Since
marijuana use can impair thinking and judgment, its users neglect to have safe sex, which
may expose them to infection to the Human Immunodeficiency Virus (HIV), or other
sexually transmitted diseases. In fact, marijuana use had been associated with increased
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unprotected sex among adolescent, exposing them to sexually transmitted diseases and
AIDS (5,6).
On the other hand, marijuana and cannabinoid derivatives have potential
therapeutic uses. Recent studies suggest that cannabinoids are likely to have a natural role
in pain modulation, control of movement, cognition, and memory (7). The office of
National Drug Control Policy, under public pressure to allow the medical use of
marijuana, funded a study by the Institute of Medicine (IOM) to evaluate the scientific
evidence for benefits and risks of using marijuana as a medicine (7). The IOM concluded
that cannabinoids would be moderately well suited for certain conditions, such as
chemotherapy-induced nausea and vomiting and poor appetite in AIDS wasting
syndrome; that cannabinoids may provide useful adjuncts to existing medications.
However, the IOM report concluded that several problems need to be addressed before
marijuana plant could be legally prescribed as a medication. Today, marijuana remains a
scheduled 1 substance, under the Controlled Substance Act (8), and there is no currently
accepted medical use of crude marijuana. However, delta-9-tetrahydrocannabinol (∆9THC), the psychoactive constituent of marijuana, has therapeutic indications approved by
the Food and Drugs Administration. Oral ∆9-THC (dronabinol) is an approved
medication to treat nausea associated with cancer chemotherapy and as an appetitestimulator for patients with wasting related to AIDS or severe cancer-related anorexia (9).
Cannabinoids have other potential therapeutic uses for a variety of disorders, including
pain, anxiety, eating disorders, movement disorders, glaucoma and cardiovascular
diseases (7, 10).
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The field of cannabinoid biology has made considerable progress over the last two
decades. Two types of cannabinoid receptors have been isolated and cloned, the CB1
receptor, which is located predominantly in the central nervous system, and the CB2,
receptor, which is associated with the immune system in the periphery. High
concentrations of CB1 receptors are located in the cerebral cortex, motor system, limbic
system and hippocampus (7, 11). In addition, two endocannabinoids, anandamide and 2arachidonoyl glycerol have been discovered (12). The CB1 receptor is thought to be
responsible for the majority of the effects in the central nervous system (CNS). CB1
receptors are frequently located on presynaptic terminals where they modulate the release
of a variety of neurotransmitters (13,14). Activation of these receptors results in
inhibition of both excitatory and inhibitory neurotransmitter release (15,16) through a
depolarization-induced suppression of the inhibition when the presysaptic
neurotransmission is inhibitory, such as GABA, and depolarization-induced suppression
of excitation when the neurotransmitter is excitatory, such as glutamine (13,14).
Cannabinoids may disrupt short-term memory by interfering with the encoding of events
in the hippocampus during memory processing (11,17). The availability of SR141617A, a
specific CB1 receptor antagonist, has confirmed cannabinoid-mediated effects on a
variety of function including cognitive function in animal (18) and human studies (19).
Oral ∆9-THC and smoked marijuana have been shown to produce similar effects
in human subjects (42,43). Studies suggest that repeated exposure to ∆9-THC or smoked
marijuana produces dependence and tolerance to at least some of the effects of cannabis
in humans (4,20,21). Several withdrawal symptoms associated with abstinence following
prolonged marijuana use include hyperirritability, tremors, sweating, auditory and visual
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hallucinations, euphoria, anxiety, negativism, insomnia or abnormal sleep patterns, and
GI distress. Studies in animals have shown that chronic administration of ∆9-THC
produces cannabinoid receptor desensitization and down-regulation (22,23,24), as well as
tolerance to cannabinoid-mediated hypoactivity, catalepsy, antinociception, and
hypothermia (22,25). However, the cognitive effects of long-term cannabis use are
insufficiently understood. Previous animal studies that assessed tolerance of the cognitive
functions to the disruptive effects of ∆9-THC have produced contradictory results (4).
Deadwyler et al. reported a complete adaptation to the disruptive effects of ∆9-THC on a
spatial discrimination version of a delayed-match-to-sample, short-term memory, in rats
chronically treated with this drug (26). Whereas others studies didn’t report tolerance to
the disruptive effects of ∆9-THC on cognitive function (27,28). It has been suggested that
cognitive impairments in long-term cannabis users might be reversible after abstinence or
cessation of use (30,31). Yet, there have been reports that prenatal exposure to marijuana
may interfere with tasks that require visual memory, analysis and integration (32,33); that
cannabinoid induces changes in gene expression (34); that marijuana use in early
adolescence was associated with poor school performance, being suspended or expelled
from school, exposure to drugs and violence, lower work aspirations, being fired from a
job, collecting welfare, being and an unmarried parent in the young adulthood (35,36,37).
The long-term neurocognitive effects of marijuana may be influenced by both the earlyonset cannabis use and the dose of marijuana consumed (36,38,39).
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Objective
The primary objective of this study is to determine whether acute administration
of ∆9-THC impairs working memory in the object recognition task in naïve mice and in
mice that are tolerant to ∆9-THC. The object recognition task was chosen over other tasks
because its design allowed the avoidance of potential conflicts associated with the mice
learning the task while receiving repeated doses of the drug.
With the increased interest in potential therapeutic uses of marijuana and
marijuana derivatives, the mounting pressure to allow medical marijuana use and the high
rate of youth abusing this drug, understanding the possible detrimental effects of chronic
marijuana on learning and memory is of critical importance.
The results of this study will contribute to the understanding of the effects of
long-term use of marijuana and marijuana derivatives on learning and memory.
Additionally, the results reported here may provide some insight as to whether these
products can be safely used in therapeutics. Finally, the outcome of this study may be
helpful in developing public health policies aimed to protect both youth and adults from
the potential short- and long-term harm of marijuana use.

Hypothesis
Tolerance to cannabinoid-induced disruption on memory in mice develops after chronic
dosing with ∆9-THC.
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Materials and methods
Subjects
Male ICR mice, obtained from Harlan Sprague Dawley, Inc, Indianapolis, IN, were used
for the purpose of this experiment. They were housed in a temperature-controlled room
(20-22oC) with a 12:12 light/dark cycle. The mice had access to food and water, and ad
libitum in their home cage. The Institutional Animal Care and Use Committee at Virginia
Commonwealth University approved all experiment procedures.
Drug
∆9-THC was provided by the National Institute on Drug Abuse (Bethesda, MD.)
∆9-THC was dissolved in a vehicle consisting of a 1:1:18 solution of
ethanol/emulphor/saline. The acute treatment was given intraperitoneally (i.p.) and the
chronic treatment was given subcutaneously (s.c.). The injection volume was 0.1ml/kg.

Object recognition task
Acute experiment
The object recognition task is a well-characterized paradigm for assessing memory that
makes use of a mouse’s natural tendency to investigate novel aspects of their
environment (40,41). All the experiments were conducted in a quiet room. The
experiment was conducted on two consecutive days. On day one, the mice received an
acclimation session in which they were allowed one hour to acclimate to the laboratory
and to the Plexiglas boxes (25 x 46 x 20 cm). A transparent sheet of Plexiglas, with three
small aeration holes (1cm of diameter), covered the box to prevent mice from escaping.
On day two, the mice were allowed one hour to acclimate to the observation room.
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Twenty minutes prior to the exposure to an object, the mice were given an i.p. injection
of a vehicle, or ∆9-THC (0.1, 0.3, 1, or 3 mg/kg). Two types of objects were used
throughout the experiment: a glass water-stopper and a metallic door pull. Following
each session, the objects were washed with alcohol and rinsed with water before being
introduced in the box. The mouse was placed in a clean Plexiglas box and one of the
objects was introduced in the box for a period of 20 minutes. The presentation of objects
was counter-balanced, such that half the mice were exposed to the water stopper and the
other half were exposed to the door pull. After the 20 minutes exposure, the object was
taken out, while the mouse remained in the box.
Five minutes later, both the familiar (object previously exposed to the mice) and a novel
object were placed in the box. The test sessions were videotaped for 5 minutes and the
time each mouse investigated the familiar and the novel objects was scored. After the 5minute session, both objects were taken out of the box and the mouse returned to its
home cage.
Investigatory behavior was defined as when a mouse sniffed the object with its snout
within 2 cm of the object or actively exploring the object. Mice that displaced any of the
objects were excluded; and mice were required to spend at least 5 seconds exploring each
object to be included in the analysis.
The mouse was considered to have formed a memory of the familiar object if it spent
more time exploring the novel object than the familiar object. If the time spent on the
familiar and the novel object was about the same, it was inferred that the mouse has
forgotten the familiar object.
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Chronic experiment
Mice were treated for one week with subcutaneous injections of either a vehicle or an
escalating dose of ∆9-THC: 10mg/kg of ∆9-THC twice a day for two days, 30mg/kg twice
a day for two days, 60mg/kg twice a day for two days and a single 60mg/kg on the
seventh day. On the seventh day, the mice were allowed to acclimate to the Plexiglas
boxes as describe in the acute experiment and given the last dose of drug immediately
after this acclimation session. Twenty-four hour after the last injection, the mice were
assessed in the object recognition task as described above.
Twenty minutes before the exposure to an object, the mice were given an i.p. injection of
a vehicle or 1 mg/kg of ∆9-THC, a dose that was found to impair memory in this task, but
failed to affect motor behavior. The rest of the testing was conducted as described in the
acute experiment.

Statistical analysis
Sigma stat and sigma plot software were used for statistical analysis and graphs.
For the analysis of acute ∆9-THC effects in the object recognition task, a paired t test was
conducted for each injection condition to assess whether the subjects spent a significantly
different amount of time investigating the familiar and novel objects. For the analysis of
the chronic treatment, a two-way ANOVA analysis was conducted on the difference in
time spent exploring the new object minus the time spent on the old object, and
significant results were further analyzed using the Tukey post hoc test. In order to
determine the ED50 values, index recognition values were computed by determining the
percentage of the time spent exploring the new object by the total time spent exploring
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both the new and the familiar objects. An index of 50 indicated no difference between the
time spent exploring the familiar and the new objects, and higher index scores indicated
that the subjects spent more time investigating the novel object than the familiar object.

Results
Effects of acute ∆9-THC
Table 1 Mean +/-SEM time spent exploring the
familiar and old objects (seconds)
Familiar object
18.6+/-1.9
Vehicle (n=11)∗
0.1mg/kg THC (n=9)∗
13.6+/-1.6
0.3mg/kg THC (n=8)
25.8+/-6.1
1mg/kg THC (n=9)
23.2+/-3.6

New object
27.7+/-3.0
24.6+/-4.9
32.3+/-4.7
25.7+/-5.5

Asterisks denote significant differences in time spent exploring the familiar and the novel object.

The acute effects of ∆9-THC on the object recognition task were assessed in mice treated
with vehicle or ∆9-THC (0.1, 0.3, 1 and 3 mg/kg); the number of mice excluded in each
group for failing to meet the criteria was respectively 4, 3, 6, 4, and 9. Because more than
half of the mice treated with 3 mg/kg of ∆9-THC were excluded (9 mice out of 13), we
suspected that mice treated with this dose were exhibiting motor impairment and were
therefore excluded from further analysis.
The mean time and standard error values each group spent investigating the objects are
presented in table 1.

17

Figure 1 Acute effects of ∆ 9-THC on object-recognition
Familiar Object
Novel Object

Difference in Investigation time (sec)

Investigation time (sec)

40

30

20

**
*

10

0
veh

0.1

0.3

18
16
14
12
10
8
6
4
2
0

1

veh

0.1

0.3

1

Dose of ∆9 -THC (mg/kg)

Figure 1 Effect of ∆9-THC on the investigation time of the familiar and the novel objects (left panel), and
on the difference in investigation time (right panel) (Time spent on novel object minus time spent on
familiar object) during the object recognition task. Each data point represents the mean time in that group
of treatment (veh (n=11), 0.1 mg/kg (n=9), 0.3 mg/kg (n=8), 1 mg/kg (n=9)). Two asterisks denote a p <
0.001 and one asterisk a p < 0.05

As shown in figure 1, the mice treated with vehicle and 0.1 mg/kg of ∆9 THC spent
significantly more time exploring the new object than the familiar object (p < 0.001 and p
< 0.05, respectively). In contrast no significant differences were found in investigation
time when the mice were treated with either 0.3 or 1 mg/kg ∆9 THC (p = 0.10 and p =
0.59, respectively), indicating that the mice had forgotten the familiar object. Although
there was trend in decreased difference in time spent investigating the objects as the dose
of ∆9 THC increased, no significant differences were found.
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The ED50 (95% CI) of ∆9-THC in disrupting memory of the familiar object was 0.5 (0.1
to1.7) mg/kg.

Effects of chronic ∆9-THC
Table 2 Mean+/-SEM time spent exploring the
familiar and old objects (seconds)
Chronic Acute
treatment treatment
Vehicle
Vehicle
THC
THC

Vehicle (n=12)∗
THC (n=9)
Vehicle (n=10)∗
THC (n=10)

Familiar
Object

New
object

14.6+/-2.8
23.3+/-5.5
17.9+/-3.5
15.3+/-1.8

22.3+/-3.2
17.9+/-3.9
28.5+/-5.0
17.7+/-4.3

Asterisks denote significant differences in time spent exploring the familiar and the novel object.

The effects of chronic treatment with ∆9-THC were assessed in mice chronically treated
with a vehicle or escalating doses of ∆9-THC. In the mice chronically treated with
vehicle, 3 mice and 6 mice, respectively, from the vehicle and ∆9-THC acute conditions
were excluded for failing to meet criteria; and in the ∆9-THC chronically treated mice, 6
mice and 5 mice were excluded from the acute vehicle and ∆9-THC conditions,
respectively.
The mean time with standard errors that each group spent exploring the familiar and the
new objects is presented in table 2.
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Figure 2 Effects of 1 mg/kg ∆ 9-THC in mice treated chronically with ∆9-THC or veh

Difference in exploring time

40

Exploratory time

Familiar Object
New object
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*

*
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1 THC Veh

Chronic Veh

1 THC

20

Acute Veh
Acute 1 mg/kg THC

15
10
5
0
-5
-10

Chronic THC

Veh

THC

Chronic Treatment

Treatment

Figure 2 Effect of acute ∆9-THC in mice chronically treated with ∆9-THC on investigation time of the
familiar and the novel objects (left panel), and on the difference in investigation time (right panel) (Time
spent on novel object minus time spent on familiar object) during the object recognition task. Each data
point represents the mean time in that group of treatment (veh/veh (n=12), veh/THC (n=9), THC/Veh
(n=10), THC/THC (n=9)). Asterisk denote a p < 0.05

A Two-Way ANOVA analysis was conducted on the difference in time spent exploring
the objects. ∆9 THC chronic treatment did not significantly affect the object recognition
task (F3,37 = 1.96, p<0.17). Additionally, there was no significant interaction between
acute and chronic treatment (F3,37 = 0.41, p<0.53). On the other hand, there was an
overall significant effect of acute treatment with 1 mg/kg of ∆9 THC on the object
recognition task (F3,37 = 7.67, p <0.009).
Planned comparisons were conducted to compare the amount of time each group spent
investigating the familiar object versus the novel object. As shown in figure 2, in the
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chronic vehicle group, mice tested with acute vehicle spent significantly more time
exploring the new object than the familiar object (p < 0.01), whereas the mice tested with
1mg/kg of ∆9 THC failed to show a significant difference in the time spent investigating
the objects (p < 0.13). In the chronic ∆9-THC group, the mice challenged with vehicle
spent significantly more time exploring the new object than the familiar object (p < 0.05),
whereas challenge with 1 mg/kg of ∆9-THC resulted in no significant differences between
the amount of time spent investigating each object (p < 0.62).

Discussion
In the present experiment, low doses of acute ∆9-THC impaired recognition of the
familiar object in the object recognition task. These results are consistent with those of
others studies using a variety of memory paradigms. Varvel et al. (18) has shown that ∆9THC disrupts working memory version of the Morris water maze at a lower dose than
that required to disrupt the reference memory or other behavioral effects such as
hypomotility, antinociception, and hypothermia. Hampson et al (11) had shown the
disruptive effects of ∆9-THC in rats on short-term memory during the performance of a
delay nonmatch-to-sample task. ∆9 THC has also been shown to produce impairment of
cognitive functions in humans (42,43,44,45). The ∆9-THC content in marijuana (46)
ranges on average between 1 and 5%, though the ∆9 THC content of some cannabis
strains are up to 12%. The plasma levels of ∆9 THC shown to impair memory in human
(42) are roughly comparable to plasma levels shown to induce memory impairment in
this task (unpublished data from Litchman’s laboratory).
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In the present experiment, mice chronically treated with ∆9 THC and challenged with a
vehicle 24 hours later recognized the familiar object in the object recognition task. This
finding suggests that the pharmacological effects of the drug had worn off. Moreover,
these results indicate that the chronic regimen employed in the current study was
insufficient to produce long-lasting cognitive deficits.
An unexpected finding of this experiment was that no tolerance to the memory disruptive
effects of ∆9 THC developed in the object recognition task. Specifically, mice chronically
treated with ∆9-THC and challenged with a ∆9-THC 24 hours later failed to remember the
familiar object. This funding suggests that, whereas tolerance to cannabinoid-induced
motor impairment, hypothermia and analgesia has shown to develop quickly (25), the
effects of chronic ∆9 THC or other cannabinoids on cognition function appears to be
resistant to tolerance, or at least tolerance to the cognitive function may develop slower
than tolerance to others cannabinoid-mediated behaviors.
Consistent with the finding reported here, Nava et al (27) had reported a lack of tolerance
to the disruptive effects of ∆9 THC in another cognitive test, the rat alternation T-maze
task. Additionally, this same study reported a lack of tolerance to the inhibition of
extracellular acetylcholine. Inhibition of acetylcholine, a major neurotransmitter in the
hippocampus, has been reported as one of the mechanism by which cannabinoids may
disrupt memory (27,47). Further, some studies in chronic cannabis users had reported a
lack of tolerance to the cognitive impairment effects of cannabinoids (38,39). Thus,
individuals who chronically take cannabinoids, either for recreational or medical reasons,
my continue to have disrupted memory while under the influence of the drug. Some
studies have even reported that chronic cannabis users exhibited impaired cognition long
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after ∆9 THC effects would have worn off (30,31). Also consistent with the finding of
this study, some studies in adolescents (35,36,37) have linked marijuana use in early
adolescence to problems in young adulthood such as not graduating from high school,
low work aspirations, being fired from a job, collecting welfare and being an unmarried
parent. Suggesting that ended marijuana to some degree was interfering with social
functioning. Even though, others studies did not found long-lasting cognitive impairment
after abstinence or cessation of use in human subjects who had been chronically exposed
to cannabinoids (48,49).
On the other hand, Deadwyler et al (26) reported a development of tolerance to the
memory disruptive effects of ∆9 THC in performance of a delayed-match-to-sample
(DMTS) task in rats chronically treated with 10 mg/kg/day ∆9 THC for up to 35 days.
However, a confound in the Deadwyler study was that the rats exhibited impaired motor
function, thus making it difficult to assess pure mnemonic function in the DMTS task.
Nonetheless, the results of this study suggest at least that a longer period of treatment
with cannabinoids may be sufficient to elicit tolerance to the disruptive effects of
cannabis on memory.
One strength of the present study was that the object recognition task used to assess
short-term memory in mice was very sensitive to drug-induced disruption, as low doses
of ∆9 THC were sufficient to impair memory, without any evidence of motor impairment.
The fact that this task can essentially be conducted in one acclimation session and one
test session simplified the experimental designed by avoiding potential conflicts
associated with the mice learning the task while receiving repeated doses of drug.
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However, in our chronic experiment, we only examined a single dose of drug at testing
using a single dosing regimen. Therefore, future studies assessing tolerance should look
at the entire dose-response relationship and examine different chronic treatment
protocols. Nonetheless, the fact that the mice treated with escalating doses of ∆9-THC
still exhibited memory impairment to a low dose of ∆9-THC suggests that tolerance did
not occur or was minimal. The fact that the observation and the scoring of investigation
time was conducted by the same individual, who was not blind to the drug, is also a
limitation of this study.

Conclusions
Acute ∆9 THC produces memory impairment and tolerance may not develop to this effect
of drug, or at least tolerance to the disruptive effects of ∆9 THC may develop slower than
that of others cannabinoid-mediated effects. These findings suggest that people who use
cannabis regularly are likely to continue to exhibit impairment of cognitive function
while under the influence of the drug.
Studies have reported that early onset use and quantity of cannabis consumed might play
a determining role in the severity of harm caused by cannabis use. Potential solutions lie
in reinforcing education on harm caused by cannabis use, which could decrease the
number of new users, and developing alternative solutions for people who wish to quit,
such as drugs for withdrawal symptoms or social support groups.
With regard to chronic use of medicinal cannabinoids, caution is needed, given the
potential for the persistent disruption of cognitive function.
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